NVO.US Novo Nordisk A/S

Healthcare Pharmaceuticals USA Stocks
55.05 USD
Close of Nov 15, 2026
34.15 61.11
Market cap
USD 184B
P/E
10.5x
P/B
5.68x
ROE
52.8%
Dividend yield
4.32%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NVO.US undervalued?

Graham number
Price55.05
Graham value33.80
Premium62.9%

NVO.US trades 62.9% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novo Nordisk A/S fundamental analysis

No fundamental analysis for Novo Nordisk A/S yet.

Novo Nordisk A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone repla…

Full company profile